Supplemented Figure Legends

Fig. S1. The mevalonate cycle and statin interaction. HMG-CoA reductase is the key and rate-limiting enzyme in the pathway. Statins competitively inhibit HMG-CoA reductase and reduce the expression of mevalonate. The products of this pathway include cholesterol, farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP). HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; HMGCRIs, HMGCR inhibitors; FTI, farnesyl transferase inhibitor.